NASDAQ:ADAP Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis $0.78 -0.03 (-3.68%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Adaptimmune Therapeutics Stock (NASDAQ:ADAP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADAP alerts:Sign Up Key Stats Today's Range$0.78▼$0.8550-Day Range$0.81▼$1.3352-Week Range$0.42▼$2.05Volume737,128 shsAverage Volume1.67 million shsMarket Capitalization$193.73 millionP/E RatioN/ADividend YieldN/APrice Target$3.38Consensus RatingBuy Company OverviewAdaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Read More… Musk warns humanity: “Obsolete” (Ad)The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. Adaptimmune Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks44th Percentile Overall ScoreADAP MarketRank™: Adaptimmune Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 648th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAdaptimmune Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Adaptimmune Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.23) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 4.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Adaptimmune Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.47% of the outstanding shares of Adaptimmune Therapeutics have been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently decreased by 13.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.47% of the outstanding shares of Adaptimmune Therapeutics have been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently decreased by 13.00%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ADAP on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.44% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.37% of the stock of Adaptimmune Therapeutics is held by institutions.Read more about Adaptimmune Therapeutics' insider trading history. Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAP Stock News HeadlinesADAP Adaptimmune Therapeutics plcOctober 18, 2024 | seekingalpha.comReviewing Adaptimmune Therapeutics (NASDAQ:ADAP) and Cardiff Oncology (NASDAQ:CRDF)October 16, 2024 | americanbankingnews.comUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Down 13.0% in SeptemberOctober 15, 2024 | americanbankingnews.comOTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCROctober 10, 2024 | msn.comAdaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutionsSeptember 25, 2024 | finance.yahoo.comAdaptimmune's T-Cell Therapy Journey: A Small Market, Big AmbitionsSeptember 12, 2024 | seekingalpha.comAdaptimmune Therapeutics PLC: Adaptimmune to Participate in Two Bank Conferences this SeptemberAugust 29, 2024 | finanznachrichten.deSee More Headlines ADAP Stock Analysis - Frequently Asked Questions How have ADAP shares performed this year? Adaptimmune Therapeutics' stock was trading at $0.7930 at the beginning of the year. Since then, ADAP stock has decreased by 1.0% and is now trading at $0.7849. View the best growth stocks for 2024 here. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics plc (NASDAQ:ADAP) issued its quarterly earnings data on Monday, August, 12th. The biotechnology company reported $0.27 EPS for the quarter. The biotechnology company had revenue of $128.23 million for the quarter, compared to analyst estimates of $58 million. Adaptimmune Therapeutics had a negative net margin of 51.25% and a negative trailing twelve-month return on equity of 116.80%. When did Adaptimmune Therapeutics IPO? Adaptimmune Therapeutics (ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are Adaptimmune Therapeutics' major shareholders? Adaptimmune Therapeutics' top institutional investors include Vontobel Holding Ltd. (0.02%). Insiders that own company stock include Gavin Wood, Garry E Menzel, Cintia Piccina, Adrian Rawcliffe, William C Bertrand Jr, John Lunger and Elliot Norry. View institutional ownership trends. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/12/2024Today10/23/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADAP CUSIPN/A CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees449Year FoundedN/APrice Target and Rating Average Stock Price Target$3.38 High Stock Price Target$4.00 Low Stock Price Target$3.00 Potential Upside/Downside+331.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,870,000.00 Net Margins-51.25% Pretax Margin-50.49% Return on Equity-116.80% Return on Assets-25.02% Debt Debt-to-Equity Ratio0.26 Current Ratio3.09 Quick Ratio3.09 Sales & Book Value Annual Sales$141.46 million Price / Sales1.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book4.62Miscellaneous Outstanding Shares246,825,000Free Float223,930,000Market Cap$193.73 million OptionableOptionable Beta2.20 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:ADAP) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.